{
  "pathway_name": "malignant-melanoma-clinical-pathways-v2-2024-508",
  "original_file": "malignant-melanoma-clinical-pathways-v2-2024-508_extracted.json",
  "processed_at": "2025-03-29T01:45:45.285377",
  "complete_summary": {
    "response": "# Comprehensive Clinical Pathway for Malignant Melanoma Management\n\n## 1. Initial Evaluation and Diagnosis\n\n### 1.1 Initial Assessment\n- **Diagnostic Workup**: Obtain diagnosis of cutaneous melanoma by a method that adequately assesses depth\n- **Initial Evaluation**: Assess clinical nodal and metastatic status (clinical N0/M0 vs. N+/M+)\n\n### 1.2 For Clinically N0, M0 Patients (No Clinical Evidence of Nodal or Distant Disease)\n- **Breslow Depth Assessment**:\n  - **\u22641mm**:\n    - **Tis (in situ)**: Surgical excision with 0.5-1 cm margins down into subcutaneous fat\n    - **T1a**: Wide local excision with 1cm margins down to fascia\n    - **T1b**: Wide local excision with 1cm margins plus consider sentinel lymph node biopsy (SLNB)\n  - **>1-2mm**: Wide local excision with 1-2cm margins plus SLNB (recommended)\n  - **\u22652mm**: Wide local excision with 2cm margins plus SLNB (recommended); consider systemic imaging for high-risk features\n\n### 1.3 For Clinically N+/M+ Patients\n- **N+, M0**: Follow Stage III pathway\n- **Any N, M1+**: Follow Metastatic First Line pathway\n\n## 2. Adjuvant Treatment and Follow-Up\n\n### 2.1 For Resectable Disease\n- **Consider**: Follow Recurrent Disease pathway\n\n### 2.2 For Non-Resectable Disease - Based on Pathological Stage\n- **Stage 0 (Tis)**: Dermatology follow-up as appropriate\n- **Stage IA/IB (T1a-T2a, N0)**:\n  - Dermatologic surveillance every 3-12 months\n  - No routine systemic imaging required\n- **Stage IB-IIC (T2b-T4b, N0)**:\n  - Dermatologic surveillance every 3-12 months\n  - Medical Oncology referral for adjuvant treatment discussion\n  - Options (based on shared decision making):\n    - Observation alone\n    - Adjuvant pembrolizumab (1 year)\n  - Cross-sectional imaging every 3-12 months for 2 years, then every 6-12 months for 3 years\n  - Consider Radiation Oncology referral for high-risk features\n- **Stage III**: Follow Stage III pathway\n- **Stage IV**: Follow Metastatic First Line pathway\n\n## 3. Stage III Disease Management\n\n### 3.1 Initial Assessment\n- **Required Testing**: BRAF mutational analysis (if not already done)\n- **Decision Point**: Nodal status assessment (SLN+ vs. Clinically Positive)\n\n### 3.2 Stage III SLN Positive Approach\n- **Initial Workup**:\n  - Systemic imaging (whole-body PET/CT or CT imaging and brain MRI)\n  - Lymph node surveillance (ultrasound every 4 months for first 2 years if possible)\n- **Treatment Options** (based on shared decision making):\n  - **Option 1**: Observation alone (preferred for Stage IIIA with small volume SLN disease <1mm)\n  - **Option 2**: Adjuvant systemic therapy (one year)\n    - If immunotherapy candidate: Pembrolizumab\n    - If not immunotherapy candidate:\n      - BRAF Positive: Dabrafenib and trametinib\n      - BRAF Negative: Observation alone\n  - **Option 3**: Radiation Oncology referral for high-risk features\n- **Observation Protocols**:\n  - **Stage IIIA**: PET/CT or CT imaging every 6-12 months for up to 5 years\n  - **Stage IIIB**: PET/CT or CT imaging and CNS imaging as necessary every 6-12 months for up to 5 years\n  - **Stage IIIC/IIID**: PET/CT or CT imaging and CNS imaging as necessary every 3-12 months for up to 5 years\n\n### 3.3 Stage III Clinically Positive Approach\n- **Initial Workup**: Systemic imaging (whole-body PET/CT and brain MRI)\n- **Decision Point**: Resectability assessment\n  - **If Resectable**:\n    - **If Immunotherapy Candidate**:\n      - Neoadjuvant approach: Nivolumab combined/nivolumab for 1 year\n      - Post-treatment imaging and assess resectability\n      - If becomes unresectable: Follow Metastatic Disease pathway\n      - If remains resectable: Wide local excision and lymph node dissection\n      - Post-resection options (if local recurrence):\n        - If immunotherapy candidate: Complete 1 year of pembrolizumab adjuvant therapy\n        - If not immunotherapy candidate and BRAF+: Dabrafenib and trametinib\n        - If not immunotherapy candidate and BRAF-: Observation alone\n  - **If Non-Resectable**:\n    - **If Immunotherapy Candidate**:\n      - Evaluate for clinical space immunotherapy:\n        - If eligible: Ipilimumab and nivolumab\n        - If not eligible: Pembrolizumab\n      - Reimaging and reassess for resection:\n        - If becomes resectable: Resection and adjuvant systemic therapy\n        - If remains non-resectable: Radiation Oncology referral and follow Metastatic First Line pathway\n    - **If Not Immunotherapy Candidate**:\n      - **BRAF+**: Dabrafenib and trametinib, then reimaging\n      - **BRAF-**: Multidisciplinary discussion\n\n## 4. Recurrent Disease Management\n\n### 4.1 Initial Assessment\n- **Required Evaluation**: Systemic imaging\n- **Decision Point**: Type of recurrence\n\n### 4.2 Management Based on Recurrence Type\n- **Primary Site Recurrence**: Re-excision to appropriate margins \u2192 Follow Adjuvant Treatment pathway\n- **Satellite or In-transit Recurrence**:\n  - Multidisciplinary discussion\n  - Surgical referral\n  - If resection achieved: Follow Adjuvant Treatment pathway\n  - If not resectable: Follow Metastatic First Line pathway\n- **Nodal Recurrence**:\n  - Multidisciplinary discussion\n  - Surgical referral\n  - If resection achieved: Follow Adjuvant Treatment pathway\n  - If not resectable: Follow Metastatic First Line pathway\n- **Distant Metastatic Disease**: Directly follow Metastatic First Line pathway\n\n## 5. Metastatic Disease Management\n\n### 5.1 Metastatic First Line\n- **Initial Assessment**: Resectability determination\n- **For Resectable Disease**:\n  - BRAF mutation analysis (if not already performed)\n  - **If Immunotherapy Candidate**:\n    - Neoadjuvant approach for 2 doses\n    - Repeat systemic imaging\n    - If disease becomes unresectable: Follow Metastatic Second Line pathway\n    - If disease remains resectable: Surgical resection\n    - Post-surgical options (based on immunotherapy candidacy):\n      - If candidate: Complete 1 year total of neoadjuvant plus adjuvant therapy\n      - If not a candidate:\n        - **BRAF+**: Dabrafenib and trametinib\n        - **BRAF-**: Observation alone\n- **For Unresectable Disease**:\n  - **Assessment**: Oligometastatic disease (disease in <4 sites)?\n    - **If Oligometastatic**:\n      - Radiation Oncology referral\n      - Assess candidacy for trial agent immunotherapy\n    - **If Not Oligometastatic**:\n      - Assess immunotherapy candidacy:\n        - **If Eligible**:\n          - Assess disease burden:\n            - If extensive burden: Ipilimumab and nivolumab\n            - If not extensive: Nivolumab and relatlimab\n        - **If Not Eligible**:\n          - Assess BRAF status:\n            - **BRAF+**: Dabrafenib and trametinib\n            - **BRAF-**: Assess for clinically indolent disease:\n              - If clinically indolent: T-VEC multipunctural therapy\n              - If not clinically indolent: Multidisciplinary discussion\n\n### 5.2 Metastatic Second Line Options\n\n#### 5.2.1 Progression After Ipilimumab and Nivolumab\n- **Assessment**: Progression in \u22645 sites?\n  - **If Yes**:\n    - Refer to Radiation Oncology or Surgery\n    - Continue systemic therapy\n  - **If No**:\n    - Assess BRAF status:\n      - **BRAF+**: Dabrafenib and trametinib\n      - **BRAF-**: Nivolumab and relatlimab\n\n#### 5.2.2 Progression After Dabrafenib and Trametinib\n- **Assessment**: Progression in \u22645 sites?\n  - **If Yes**:\n    - Refer to Radiation Oncology or Surgery\n    - Continue systemic therapy\n  - **If No**:\n    - Assess candidacy for dual agent immunotherapy:\n      - **If Candidate**:\n        - Evaluate disease burden:\n          - If extensive: Ipilimumab and nivolumab\n          - If not extensive: Nivolumab and relatlimab\n      - **If Not Candidate**:\n        - Assess candidacy for single agent immunotherapy:\n          - If candidate: Pembrolizumab\n          - If not candidate: Assess for clinically palpable disease:\n            - If palpable: T-VEC/intralesional therapy\n            - If not palpable: Multidisciplinary discussion\n\n#### 5.2.3 Progression After PD-1 Alone\n- **Assessment**: Progression in <5 sites?\n  - **If Yes**: Refer to Radiation Oncology/Surgery and continue systemic therapy\n  - **If No**: Assess BRAF status:\n    - **BRAF+**:\n      - Dabrafenib and trametinib\n      - Then assess disease burden:\n        - If extensive: Ipilimumab and nivolumab\n        - If not extensive: Multidisciplinary discussion\n    - **BRAF-**:\n      - Assess candidacy for dual agent immunotherapy:\n        - If candidate: Assess disease burden:\n          - If extensive: Ipilimumab and nivolumab\n          - If not extensive: Nivolumab and relatlimab\n        - If not candidate: Multidisciplinary discussion\n\n#### 5.2.4 Progression After Nivolumab and Relatlimab\n- **Assessment**: Progression in \u22645 sites?\n  - **If Yes**:\n    - Refer to Radiation Oncology or Surgery\n    - Continue systemic therapy\n  - **If No**:\n    - Assess BRAF status:\n      - **BRAF+**: Dabrafenib and trametinib\n      - **BRAF-**: Assess candidacy for dual agent immunotherapy:\n        - If candidate: Ipilimumab and nivolumab\n        - If not candidate: Multidisciplinary discussion\n\n## 6. Special Anatomical Considerations\n\n### 6.1 Intracranial Melanoma\n- **Initial Referrals**: Palliative Care, Radiation Oncology, Neurosurgery\n- **Assessment**: Symptom status\n  - **If Symptomatic**: Steroid therapy as necessary and multidisciplinary discussion\n  - **If Asymptomatic**:\n    - Assess metastasis size:\n      - **If <3cm**: Evaluate prior systemic therapy:\n        - If prior therapy: Multidisciplinary discussion, locoregional treatment, follow Metastatic Second Line pathway\n        - If no prior therapy: Assess candidacy for initial systemic therapy:\n          - If candidate: Follow Metastatic First Line pathway\n          - If not candidate: Assess if lesions are amenable to SRS with no leptomeningeal disease:\n            - If yes: Option for resection or stereotactic radiosurgery followed by Metastatic First Line pathway\n            - If no: Whole brain radiation with hippocampal sparing and memantine followed by Metastatic First Line pathway\n\n### 6.2 Mucosal Melanoma\n- **Initial Evaluation**: Systemic imaging and multidisciplinary discussion\n- **Decision Point**: Resectability assessment\n  - **If Resectable**:\n    - Resection of primary tumor and lymph node dissection\n    - Radiation Oncology referral\n    - Follow Adjuvant pathway and Medical Oncology referral\n  - **If Unresectable**:\n    - Radiation Oncology referral\n    - Follow Unresectable pathway and Medical Oncology referral\n    - KIT mutation testing required (consider KIT-targeting therapy)\n\n### 6.3 Ocular Melanoma\n- **Decision Point**: Clinical site of disease\n  - **If Uveal**:\n    - Ophthalmologic examination including ultrasound\n    - CT scan of chest, abdomen, and pelvis\n    - **Treatment Options** (based on shared decision making):\n      - Radiation therapy with optional gene risk stratification\n      - Enucleation with optional gene risk stratification\n    - **Post-Treatment**:\n      - Medical Oncology referral\n      - Continued ophthalmologic care\n    - **Risk-Based Surveillance**:\n      - **High Risk** (Class II, monosomy 3, gain of 8q, BAP1 mutation, T4):\n        - Alternating CT chest/abdomen/pelvis and liver ultrasound every 3 months\n      - **Medium Risk** (Class IB, SF3B1 mutation, T2 and T3):\n        - CT chest/abdomen/pelvis every 6 months\n      - **Low Risk** (Class IA, disomy 3, gain of 6p, EIF1AX mutation, T1):\n        - CT chest/abdomen/pelvis annually\n  - **If Conjunctival**: Follow Mucosal pathway\n\n### 6.4 Uveal Metastatic or Recurrent\n- **Initial Testing**: High resolution testing for HLA-A*02:01 status\n- **Decision Point**: Hepatic disease assessment\n  - **If Hepatic Disease Present**:\n    - Assess if disease is limited to liver:\n      - **If Yes**:\n        - Patient preference after shared decision making\n        - Options: Radiation Oncology or Interventional Radiology referral\n        - After liver-directed therapy, monitor for progression:\n          - If progression: Check HLA-A*02:01 status:\n            - If positive: Tebentafusp-tebn\n            - If negative: Follow Metastatic pathway\n          - If no progression: Continue current therapy or observation\n      - **If No** (not limited to liver):\n        - Check HLA-A*02:01 status:\n          - If positive: Tebentafusp-tebn\n          - If negative: Follow Metastatic pathway\n  - **If Hepatic Disease Absent**:\n    - Assess if disease is resectable:\n      - **If Yes**: Resection followed by observation\n      - **If No**: Determine if candidate for radiation:\n        - If yes: Radiation Oncology referral\n        - If no: Check HLA-A*02:01 status:\n          - If positive: Tebentafusp-tebn\n          - If negative: Follow Metastatic pathway\n\n## 7. Molecular Testing Guidelines\n\n### 7.1 Testing Approach by Melanoma Type\n- **Initial Classification**: Determine melanoma anatomic site/type\n\n#### 7.1.1 Ocular Melanoma\n- **Testing**: Gene expression profiling, chromosomal microarray, or CGP\n- **For Recurrent/Metastatic Uveal Melanoma**: High resolution HLA-A*02:01 testing\n\n#### 7.1.2 Mucosal Melanoma\n- **Testing**: BRAF V600E/K PCR and KIT PCR\n\n#### 7.1.3 Cutaneous Melanoma (Stage III-IV or Unresectable)\n- **Testing**: BRAF V600E/K PCR\n\n#### 7.1.4 Acral/Lentiginous Melanoma (Stage III-IV or Unresectable)\n- **Testing**: BRAF V600E/K PCR and KIT PCR\n\n### 7.2 Molecular Testing Specifications\n- **Cutaneous Melanoma**:\n  - BRAF V600E/K PCR (tumor tissue or blood)\n  - BRAF V600E mutation IHC (tumor tissue)\n\n- **Mucosal Melanoma**:\n  - BRAF V600E/K PCR, KIT PCR (tumor tissue or blood)\n  - BRAF V600E mutation IHC (tumor tissue)\n  - Optional risk stratification: Gene expression profiling or chromosomal micro array\n\n- **Ocular (Uveal) Melanoma**:\n  - Somatic NGS: CGP using DNA and RNA methodology\n  - Tests for: GNAQ, GNA11, BAP1, PLCB4, CYSLTR2, SF3B1, EIF1AX\n  - For recurrent/metastatic cases: HLA-A*02:01 testing\n\n- **Acral/Lentiginous Melanoma**:\n  - BRAF V600E/K PCR, KIT PCR (tumor tissue or blood)\n  - BRAF V600E mutation IHC (tumor tissue)\n\n## 8. Key Clinical Considerations\n\n### 8.1 Immunotherapy Candidacy\nPatients should not have:\n- Active autoimmune disease\n- Primary immune deficiency\n- Concurrent immunosuppression (including prednisone >10mg/day)\n- Prior allogeneic hematopoietic stem cell transplantation\n- Solid organ transplant\n- For dual agent immunotherapy: ECOG performance status 0-1\n\n### 8.2 Disease Burden Definitions\n- **Extensive Disease Burden**: Presence of brain metastases or clinically symptomatic sites of disease\n\n### 8.3 BRAF Inhibitor Options\n- Primary recommendation: Dabrafenib and trametinib\n- Alternative options for intolerance/preference:\n  - Encorafenib and binimetinib\n  - Vemurafenib and cobimetinib\n\n### 8.4 Surveillance Protocols\n- **Cross-sectional imaging**: Includes PET/CT or CT imaging of chest, abdomen, pelvis\n- **Stage-specific imaging frequency**:\n  - **Stage 0-IB (T1a-T2a, N0)**: No routine systemic imaging\n  - **Stage IB-IIC (T2b-T4b, N0)**: Every 3-12 months for 2 years, then every 6-12 months for 3 years\n  - **Stage IIIA**: Every 6-12 months for up to 5 years\n  - **Stage IIIB**: Every 6-12 months for up to 5 years\n  - **Stage IIIC/IIID/IV**: Every 3-12 months for up to 5 years\n\n### 8.5 Universal Considerations\n- **Clinical trials** should always be considered at all pathway decision points\n- **Palliative Care** referral should be considered throughout treatment course\n- **Multidisciplinary discussion** is recommended for complex cases\n- **Patient preference** after shared decision making is essential for treatment selection\n\nThis comprehensive clinical pathway provides guidance for the management of melanoma across all disease stages and anatomical sites, with emphasis on personalized treatment approaches based on molecular profile, disease extent, and individual patient factors.",
    "thinking": "To create a comprehensive summary of the malignant melanoma clinical pathway, I'll need to synthesize all the information from the page analyses into a cohesive, logically structured document. I'll organize this by the patient journey through the clinical pathway, starting with initial evaluation and moving through the various decision points and treatment branches.\n\nLet me organize the key components:\n\n1. Introduction/Overview\n2. Initial Evaluation and Diagnosis\n3. Staging and Treatment Pathways\n   - Early Stage Disease (0-II)\n   - Stage III Disease\n     - SLN Positive\n     - Clinically Positive\n   - Metastatic Disease Management\n     - First-line Treatment\n     - Second-line Treatment Options (based on progression after different first-line therapies)\n   - Recurrent Disease\n4. Special Anatomical Considerations\n   - Intracranial\n   - Mucosal\n   - Ocular\n   - Uveal Metastatic or Recurrent\n5. Molecular Testing Guidelines\n6. Follow-up Protocols\n7. Appendix: Key Clinical Considerations\n\nNow I'll integrate the details from each page analysis into this structure, ensuring all critical decision points and treatment options are included."
  }
}